EBV-Specific Anti-PD1 TCR-T Cells in the Treatment of EBV-Positive NHSCC

NCT04139057 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

10

Enrollment

OTHER

Sponsor class

Conditions

Head and Neck Squamous Cell Carcinoma

Interventions

DRUG: EBV-specific TCR-T cell with anti-PD1 auto-secreted element

Sponsor

Xinqiao Hospital of Chongqing

Collaborators

[object Object]